Literature DB >> 23943799

Notch1 is required for Kras-induced lung adenocarcinoma and controls tumor cell survival via p53.

Silvia Licciulli1, Jacqueline L Avila, Linda Hanlon, Scott Troutman, Matteo Cesaroni, Smitha Kota, Brian Keith, M Celeste Simon, Ellen Puré, Fred Radtke, Anthony J Capobianco, Joseph L Kissil.   

Abstract

The Notch pathway has been implicated in a number of malignancies with different roles that are cell- and tissue-type dependent. Notch1 is a putative oncogene in non-small cell lung cancer (NSCLC) and activation of the pathway represents a negative prognostic factor. To establish the role of Notch1 in lung adenocarcinoma, we directly assessed its requirement in Kras-induced tumorigenesis in vivo using an autochthonous model of lung adenocarcinoma with concomitant expression of oncogenic Kras and deletion of Notch1. We found that Notch1 function is required for tumor initiation via suppression of p53-mediated apoptosis through the regulation of p53 stability. These findings implicate Notch1 as a critical effector in Kras-driven lung adenocarcinoma and as a regulator of p53 at a posttranslational level. Moreover, our study provides new insights to explain, at a molecular level, the correlation between Notch1 activity and poor prognosis in patients with NSCLC carrying wild-type p53. This information is critical for design and implementation of new therapeutic strategies in this cohort of patients representing 50% of NSCLC cases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23943799      PMCID: PMC3791518          DOI: 10.1158/0008-5472.CAN-13-1384

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  52 in total

1.  Surfing the p53 network.

Authors:  B Vogelstein; D Lane; A J Levine
Journal:  Nature       Date:  2000-11-16       Impact factor: 49.962

2.  Chromosome 19 translocation, overexpression of Notch3, and human lung cancer.

Authors:  T P Dang; A F Gazdar; A K Virmani; T Sepetavec; K R Hande; J D Minna; J R Roberts; D P Carbone
Journal:  J Natl Cancer Inst       Date:  2000-08-16       Impact factor: 13.506

3.  Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway.

Authors:  Asra Mirza; Marnie McGuirk; Tish N Hockenberry; Qun Wu; Hena Ashar; Stuart Black; Shu Fen Wen; Luquan Wang; Paul Kirschmeier; W Robert Bishop; Loretta L Nielsen; Cecil B Pickett; Suxing Liu
Journal:  Oncogene       Date:  2002-04-18       Impact factor: 9.867

4.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

Authors:  E L Jackson; N Willis; K Mercer; R T Bronson; D Crowley; R Montoya; T Jacks; D A Tuveson
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

5.  HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation.

Authors:  B P Zhou; Y Liao; W Xia; Y Zou; B Spohn; M C Hung
Journal:  Nat Cell Biol       Date:  2001-11       Impact factor: 28.824

6.  Expression of p14ARF overcomes tumor resistance to p53.

Authors:  Wenge Lu; Jiayuh Lin; Jiandong Chen
Journal:  Cancer Res       Date:  2002-03-01       Impact factor: 12.701

7.  A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus.

Authors:  L D Mayo; D B Donner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

Review 8.  Control of p53 ubiquitination and nuclear export by MDM2 and ARF.

Authors:  Y Zhang; Y Xiong
Journal:  Cell Growth Differ       Date:  2001-04

9.  Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia.

Authors:  Teresa Palomero; Maria Luisa Sulis; Maria Cortina; Pedro J Real; Kelly Barnes; Maria Ciofani; Esther Caparros; Jean Buteau; Kristy Brown; Sherrie L Perkins; Govind Bhagat; Archana M Agarwal; Giuseppe Basso; Mireia Castillo; Satoru Nagase; Carlos Cordon-Cardo; Ramon Parsons; Juan Carlos Zúñiga-Pflücker; Maria Dominguez; Adolfo A Ferrando
Journal:  Nat Med       Date:  2007-09-16       Impact factor: 53.440

10.  Therapeutic effect of γ-secretase inhibition in KrasG12V-driven non-small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK.

Authors:  Pablo J Fernández-Marcos; Daniel Herranz; Antonio Maraver; Maribel Muñoz-Martin; Gonzalo Gomez-Lopez; Marta Cañamero; Francisca Mulero; Diego Megías; Marta Sanchez-Carbayo; Jie Shen; Montserrat Sanchez-Cespedes; Teresa Palomero; Adolfo Ferrando; Manuel Serrano
Journal:  Cancer Cell       Date:  2012-08-14       Impact factor: 31.743

View more
  56 in total

Review 1.  Genetically Engineered Mouse Models of K-Ras-Driven Lung and Pancreatic Tumors: Validation of Therapeutic Targets.

Authors:  Matthias Drosten; Carmen Guerra; Mariano Barbacid
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

2.  RUMI is a novel negative prognostic marker and therapeutic target in non-small-cell lung cancer.

Authors:  May Chammaa; Agnes Malysa; Carlos Redondo; Hyejeong Jang; Wei Chen; Gerold Bepler; Rodrigo Fernandez-Valdivia
Journal:  J Cell Physiol       Date:  2018-06-28       Impact factor: 6.384

3.  Co-Expression Analysis Reveals Mechanisms Underlying the Varied Roles of NOTCH1 in NSCLC.

Authors:  Sara L Sinicropi-Yao; Joseph M Amann; David Lopez Y Lopez; Ferdinando Cerciello; Kevin R Coombes; David P Carbone
Journal:  J Thorac Oncol       Date:  2018-11-05       Impact factor: 15.609

4.  Musashi-2 (MSI2) supports TGF-β signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis.

Authors:  Alexander E Kudinov; Alexander Deneka; Anna S Nikonova; Tim N Beck; Young-Ho Ahn; Xin Liu; Cathleen F Martinez; Fred A Schultz; Samuel Reynolds; Dong-Hua Yang; Kathy Q Cai; Khaled M Yaghmour; Karmel A Baker; Brian L Egleston; Emmanuelle Nicolas; Adaeze Chikwem; Gregory Andrianov; Shelly Singh; Hossein Borghaei; Ilya G Serebriiskii; Don L Gibbons; Jonathan M Kurie; Erica A Golemis; Yanis Boumber
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-06       Impact factor: 11.205

5.  p53 Modulates Notch Signaling in MCF-7 Breast Cancer Cells by Associating With the Notch Transcriptional Complex Via MAML1.

Authors:  Jieun Yun; Ingrid Espinoza; Antonio Pannuti; Damian Romero; Luis Martinez; Mary Caskey; Adina Stanculescu; Maurizio Bocchetta; Paola Rizzo; Vimla Band; Hamid Band; Hwan Mook Kim; Song-Kyu Park; Keon Wook Kang; Maria Laura Avantaggiati; Christian R Gomez; Todd Golde; Barbara Osborne; Lucio Miele
Journal:  J Cell Physiol       Date:  2015-12       Impact factor: 6.384

6.  NOTCH1 signaling promotes chemoresistance via regulating ABCC1 expression in prostate cancer stem cells.

Authors:  Cheng Liu; Zhuohang Li; Liangkuan Bi; Kuiqing Li; Bangfen Zhou; Chen Xu; Jian Huang; Kewei Xu
Journal:  Mol Cell Biochem       Date:  2014-04-30       Impact factor: 3.396

7.  Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.

Authors:  Chiara Ambrogio; Gonzalo Gómez-López; Mattia Falcone; August Vidal; Ernest Nadal; Nicola Crosetto; Rafael B Blasco; Pablo J Fernández-Marcos; Montserrat Sánchez-Céspedes; Xiaomei Ren; Zhen Wang; Ke Ding; Manuel Hidalgo; Manuel Serrano; Alberto Villanueva; David Santamaría; Mariano Barbacid
Journal:  Nat Med       Date:  2016-02-08       Impact factor: 53.440

Review 8.  Non-small-cell lung cancers: a heterogeneous set of diseases.

Authors:  Zhao Chen; Christine M Fillmore; Peter S Hammerman; Carla F Kim; Kwok-Kin Wong
Journal:  Nat Rev Cancer       Date:  2014-08       Impact factor: 60.716

9.  Pulmonary mucinous adenocarcinomas: architectural patterns in correlation with genetic changes, prognosis and survival.

Authors:  Abidin Geles; Ulrike Gruber-Moesenbacher; Franz Quehenberger; Claudia Manzl; Mohamed Al Effah; Elisabeth Grygar; Freyja Juettner-Smolle; Helmut H Popper
Journal:  Virchows Arch       Date:  2015-10-08       Impact factor: 4.064

10.  Gamma Secretase Inhibition by BMS-906024 Enhances Efficacy of Paclitaxel in Lung Adenocarcinoma.

Authors:  Katherine M Morgan; Bruce S Fischer; Francis Y Lee; Jamie J Shah; Joseph R Bertino; Jeffrey Rosenfeld; Amartya Singh; Hossein Khiabanian; Sharon R Pine
Journal:  Mol Cancer Ther       Date:  2017-10-04       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.